Armistice Capital LLC purchased a new stake in shares of GRI Bio, Inc. (NASDAQ:GRI – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned about 9.23% of GRI Bio at the end of the most recent quarter.
GRI Bio Stock Down 10.2 %
NASDAQ:GRI opened at 0.45 on Friday. The stock’s 50 day simple moving average is 0.63 and its two-hundred day simple moving average is 3.68. GRI Bio, Inc. has a 1 year low of 0.40 and a 1 year high of 161.98.
GRI Bio (NASDAQ:GRI – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported -4.92 EPS for the quarter.
GRI Bio Company Profile
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
Featured Articles
- Five stocks we like better than GRI Bio
- How to buy stock: A step-by-step guide for beginners
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Best Stocks Under $10.00
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Financial Services Stocks Investing
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Want to see what other hedge funds are holding GRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRI Bio, Inc. (NASDAQ:GRI – Free Report).
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.